The α-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes

Nutrition

Volumn 25, Issue 6, 2009, Pages 657-667

  Fukaya, Nanae ^a   Mochizuki, Kazuki ^a   Shimada, Masaya ^a   Goda, Toshinao ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Glucose fluctuations; Interleukin 1 ; Miglitol; Peripheral leukocytes; S100 proteins

Indexed keywords

1,5 ANHYDROSORBITOL; CALCYCLIN; CALGRANULIN A; CALGRANULIN B; CALVASCULIN; GLUCOSE; INTERLEUKIN 1BETA; MIGLITOL; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; LEUKOCYTE; MALE; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; UPREGULATION;

RATTUS;

EID: 67349181083     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2008.11.015     Document Type: Article

References (40)

1. Giugliano D., Ceriello A., and Esposito K. Glucose metabolism and hyperglycemia. Am J Clin Nutr 87 (2008) 217S-222
2. Shoelson S.E., Lee J., and Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 116 (2006) 1793-1801
3. Lu L., Zhang Q., Pu L.J., Xu X.W., Zhang R.Y., Zhang J.S., et al. Elevation of tumor necrosis factor-α, interleukin-1β and interleukin-6 levels in aortic intima of Chinese Guizhou minipigs with streptozotocin-induced diabetes. Chin Med J (Engl) 120 (2007) 479-484
4. Wen Y., Gu J., Li S.L., Reddy M.A., Natarajan R., and Nadler J.L. Elevated glucose and diabetes promote interleukin-12 cytokine gene expression in mouse macrophages. Endocrinology 147 (2006) 2518-2525
5. Hui H., Dotta F., Di Mario U., and Perfetti R. Role of caspases in the regulation of apoptotic pancreatic islet beta-cells death. J Cell Physiol 200 (2004) 177-200
6. Jorns A., Gunther A., Hedrich H.J., Wedekind D., Tiedge M., and Lenzen S. Immune cell infiltration, cytokine expression, and β-cell apoptosis during the development of type 1 diabetes in the spontaneously diabetic LEW. 1AR1/Ztm-iddm rat. Diabetes 54 (2005) 2041-2052
7. Montolio M., Biarnes M., Tellez N., Escoriza J., Soler J., and Montanya E. Interleukin-1β and inducible form of nitric oxide synthase expression in early syngeneic islet transplantation. J Endocrinol 192 (2007) 169-177
8. Hoge M., and Amar S. Role of interleukin-1 in bacterial atherogenesis. Drugs Today (Barc) 42 (2006) 683-688
9. Mahmoudi M., Curzen N., and Gallagher P.J. Atherogenesis: the role of inflammation and infection. Histopathology 50 (2007) 535-546
10. Schmidt D.D., Frommer W., Junge B., Muller L., Wingender W., Truscheit E., and Schafer D. α-glucosidase inhibitors. New complex oligosaccharides of microbial origin. Naturwissenschaften 64 (1977) 535-536
11. Caspary W.F., and Graf S. Inhibition of human intestinal alpha-glucoside hydrolases by a new complex oligosaccharide. Res Exp Med (Berl) 175 (1979) 1-6
12. Puls W., Keup U., Krause H.P., Muller L., and Schmidt D.D. Pharmacology of a glucosidase inhibitor. Front Horm Res 7 (1980) 235-247
13. Goda T., Yamada K., Hosoya N., and Moriuchi S. Effects of α-glucosidase inhibitor BAY g 5421 on rat intestinal disaccharidases. J Jpn Soc Nutr Food Sci 34 (1981) 139-143
14. Horii S. Valiolamine and its N-substituted derivatives, alpha-D-glucosidase inhibitors: from validamycins to voglibose (AO-128), an antidiabetic agent. J Takeda Res Lab 52 (1993) 1-26
15. Puls W., Krause H.P., Muller L., Schutt H., Sitt R., and Thomas G. Inhibitors of the rate of carbohydrate and lipid absorption by the intestine. Int J Obes Relat Metab Disord 8 suppl 1 (1984) 181-190
16. Samulitis B.K., Goda T., Lee S.M., and Koldovsky O. Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine. Drugs Exp Clin Res 13 (1987) 517-524
17. Goda T., Suruga K., Komori A., Kuranuki S., Mochizuki K., Makita Y., and Kumazawa T. Effects of miglitol, an α-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats. Br J Nutr 98 (2007) 702-710
18. Azuma K., Toyofuku Y., Iesaki T., Otsuka A., Tanaka A., Mita T., et al. Acarbose, an α-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation. Biochem Biophys Res Commun 345 (2006) 688-693
19. Koyama M., Wada R., Mizukami H., Sakuraba H., Odaka H., Ikeda H., and Yagihashi S. Inhibition of progressive reduction of islet β-cell mass in spontaneously diabetic Goto-Kakizaki rats by alpha-glucosidase inhibitor. Metabolism 49 (2000) 347-352
20. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., and Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2077
21. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., and Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290 (2003) 486-494
22. Zeymer U., Schwarzmaier-D'assie A., Petzinna D., and Chiasson J.L. Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy. Eur J Cardiovasc Prev Rehabil 11 (2004) 412-415
23. Honma K., Mochizuki K., and Goda T. Carbohydrate/fat ratio in the diet alters histone acetylation on the sucrase-isomaltase gene and its expression in mouse small intestine. Biochem Biophys Res Commun 357 (2007) 1124-1129
24. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
25. Gautam N., Downes G.B., Yan K., and Kisselev O. The G-protein β-γ complex. Cell Signal 10 (1998) 447-455
26. Najib S., Martin-Romero C., Gonzalez-Yanes C., and Sanchez-Margalet V. Role of Sam68 as an adaptor protein in signal transduction. Cell Mol Life Sci 62 (2005) 36-43
27. Teran L.M. CCL chemokines and asthma. Immunol Today 21 (2000) 235-242
28. Agell N., Bachs O., Rocamora N., and Villalonga P. Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin. Cell Signal 14 (2002) 649-654
29. Foell D., Frosch M., Sorg C., and Roth J. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 344 (2004) 37-51
30. Bouma G., Coppens J.M., Lam-Tse W.K., Luini W., Sintnicolaas K., Levering W.H., et al. An increased MRP8/14 expression and adhesion, but a decreased migration towards proinflammatory chemokines of type 1 diabetes monocytes. Clin Exp Immunol 141 (2005) 509-517
31. Bouma G., Lam-Tse W.K., Wierenga-Wolf A.F., Drexhage H.A., and Versnel M.A. Increased serum levels of MRP-8/14 in type 1 diabetes induce an increased expression of CD11b and an enhanced adhesion of circulating monocytes to fibronectin. Diabetes 53 (2004) 1979-1986
32. Sunahori K., Yamamura M., Yamana J., Takasugi K., Kawashima M., Yamamoto H., et al. The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther 8 (2006) R69
33. Kawasaki T., Yamanouchi T., Kashiwabara A., Inoue T., Yoshimura T., Fujimori S., et al. The influence of traditional Chinese herbal drugs on serum 1,5-anhydroglucitol levels. Diabetes Res Clin Pract 50 (2000) 97-101
34. Yoshioka K., Azukari K., Yoshida T., and Kondo M. Rapid improvement of serum 1,5-anhydroglucitol concentrations after administration of α-glucosidase inhibitor. Diabetes Care 20 (1997) 462
35. Gerstein H.C., Miller M.E., Byington R.P., Goff Jr. D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
36. Bonora E. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl 29 (2002) 5-11
37. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
38. Dluhy R.G., and McMahon G.T. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 358 (2008) 2630-2633
39. Kaul S., and Diamond G.A. Rosiglitazone and cardiovascular risk. Curr Atheroscler Rep 10 (2008) 398-404
40. Fujimoto S., Mochizuki K., Shimada S., Murayama Y., and Goda T. Variation in gene expression of inflammatory cytokines in leukocyte-derived cells of high-fat-diet-induced insulin-resistant rats. Biosci Biotechnol Biochem 72 (2008) 2572-2579